Kodiak Sciences Inc. (KOD)

NASDAQ: KOD · IEX Real-Time Price · USD
3.600
-0.290 (-7.46%)
At close: Apr 17, 2024, 4:00 PM
3.700
+0.100 (2.78%)
After-hours: Apr 17, 2024, 7:59 PM EDT
-7.46%
Market Cap 189.03M
Revenue (ttm) n/a
Net Income (ttm) -260.49M
Shares Out 52.51M
EPS (ttm) -4.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 607,643
Open 3.930
Previous Close 3.890
Day's Range 3.580 - 3.930
52-Week Range 1.370 - 9.800
Beta 2.13
Analysts Sell
Price Target 3.25 (-9.72%)
Earnings Date May 13, 2024

About KOD

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative dia... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 4, 2018
Employees 111
Stock Exchange NASDAQ
Ticker Symbol KOD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for KOD stock is "Sell." The 12-month stock price forecast is $3.25, which is a decrease of -9.72% from the latest price.

Price Target
$3.25
(-9.72% downside)
Analyst Consensus: Sell
Stock Forecasts

News

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Three clinical programs present diversified opportunities in and outside the existing anti-VEGF market and are being progressed toward Phase 3 value inflection points   New Phase 3 GLOW2 study of tarc...

20 days ago - PRNewsWire

Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024

PALO ALTO, Calif. , March 26, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics ...

23 days ago - PRNewsWire

Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting

PALO ALTO, Calif. , Jan. 30, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics t...

2 months ago - PRNewsWire

Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

PALO ALTO, Calif. , Jan. 4, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to...

3 months ago - PRNewsWire

Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

PALO ALTO, Calif. , Nov. 21, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics t...

5 months ago - PRNewsWire

Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights

PALO ALTO, Calif. , Nov. 14, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2023.

5 months ago - PRNewsWire

Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission

Primary endpoint and all key secondary endpoints met with high statistical significance in GLOW study. With 6-month dosing of all patients, tarcocimab and the ABC platform continue to demonstrate diff...

5 months ago - PRNewsWire

KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING

PALO ALTO, Calif. , Nov. 1, 2023 /PRNewswire/ -- Kodiak Sciences Inc (NASDAQ: KOD) today announced that data from tarcocimab tedromer will be presented during the annual meeting of the American Academ...

6 months ago - PRNewsWire

Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society

PALO ALTO, Calif. , Oct. 11, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics t...

6 months ago - PRNewsWire

Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

PALO ALTO, Calif. , Sept. 8, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics t...

7 months ago - PRNewsWire

New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion

Tarcocimab demonstrated strong durability, matched efficacy and comparable safety versus aflibercept in a head-to-head comparative pivotal trial over one-year After 4 initiating doses in the first 6 m...

8 months ago - PRNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kodiak Sciences Inc. - KOD

NEW YORK , Aug. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kodiak Sciences Inc. ("Kodiak" or the "Company") (NASDAQ: KOD). Such investors are advised to c...

8 months ago - PRNewsWire

Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights

PALO ALTO, Calif. , Aug. 14, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics t...

8 months ago - PRNewsWire

Kodiak Sciences scraps development of eye disorder drug

Kodiak Sciences Inc decided to discontinue development of its experimental drug to treat a type of eye disorder, sending its shares tumbling 40% in premarket trading on Monday.

9 months ago - Reuters

Kodiak Sciences stock plunges into record-low territory after decision to discontinue wet AMD treatment

Shares of Kodiak Sciences Inc. KOD, +2.97% plummeted 56.9% into record-low territory, and to pace all premarket declines, after the California-based biotechnology company said it decided to discontinu...

9 months ago - Market Watch

Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program

PALO ALTO, Calif. , July 24, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ: KOD) announced today topline results from three Phase 3 studies of tarcocimab tedromer, a novel antibody biopolymer conj...

9 months ago - PRNewsWire

Kodiak Sciences to Present at Upcoming Investor Conferences

PALO ALTO, Calif., May 30, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to ...

11 months ago - PRNewsWire

Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights

PALO ALTO, Calif. , May 15, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to...

1 year ago - PRNewsWire

Kodiak Sciences Announces Upcoming Presentations on its Product and Research Pipeline at ARVO 2023 Annual Meeting

PALO ALTO, Calif. , April 21, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics ...

1 year ago - PRNewsWire

Kodiak Sciences Expands Development Pipeline with Treatment of First Patient in Phase 1 Clinical Study of KSI-501, an Investigational Bispecific Antibody Biopolymer Conjugate for Retinal Diseases

PALO ALTO, Calif. , April 3, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics t...

1 year ago - PRNewsWire

Kodiak Sciences Announces Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

PALO ALTO, Calif. , March 28, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics ...

1 year ago - PRNewsWire

Kodiak Sciences Announces Upcoming Presentation of KSI-301 (tarcocimab tedromer) Clinical Data and Antibody Biopolymer Conjugate Development Programs at the Angiogenesis, Exudation and Degeneration 2023 Virtual Meeting

PALO ALTO, Calif. , Feb. 9, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to...

1 year ago - PRNewsWire

Kodiak Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

PALO ALTO, Calif. , Jan. 4, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to...

1 year ago - PRNewsWire

Kodiak Sciences to Present at the Evercore ISI 5th Annual HealthCONx Conference

PALO ALTO, Calif. , Nov. 16, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics t...

1 year ago - PRNewsWire

Kodiak Sciences Announces Third Quarter 2022 Financial Results and Recent Business Highlights

PALO ALTO, Calif. , Nov. 9, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to...

1 year ago - PRNewsWire